Poster Presentations Session IV
Poster Presentations Session IV Tuesday, June 3, 2014
POSTERS SET-UP: 3:30 PM - 3:45 PM
POSTERS DISPLAY HOURS: 3:45 PM - 7:45 PM
POSTER AUTHOR DISCUSSION: 6:45 PM - 7:45 PM
POSTERS DISMANTLE: 7:45 PM


Poster display locations are shown below the poster codes
RESEARCH ON METHODS - Clinical Outcomes Methods
PRM1
A1
COMPARATIVE ASSESSMENT OF HEALTH IMPACT OF PREVENTION FOR 9 DIFFERENT CANCERS
Hung M1, Lai W2, Hwang J3, Wang J4
1Department of Public Health, National Cheng Kung University Medical College, Tainan, Taiwan, 2Department of Surgery, National Cheng Kung University Hospital, College of Medicine, National Cheng Kung University, Tainan, Taiwan, 3Institute of Statistical Science, Academia Sinica, Taipei, Taiwan, 4National Cheng Kung University College of Medicine, Tainan, Taiwan

PRM2
A2
EVIDENCE-BASED PRESCRIBING: USING EXISTING DATA ON BENEFITS AND HARMS TO CHOOSE AMONG MULTIPLE DRUGS
Naci H1, van Valkenhoef G2, Higgins JP3, Fleurence R4, Ades A3
1London School of Economics, London, UK, 2University of Groningen, Groningen, The Netherlands, 3University of Bristol, Bristol, UK, 4Patient-Centered Outcomes Research Institute (PCORI), Washington, DC, USA

PRM3
A3
A COMPARISON OF 3 ASSESSMENTS IN THE TREATMENT OF ROSACEA IN THE CONTEXT OF A COMPARATIVE EFFECTIVENESS STUDY
Kendall J, Winkelman W
Galderma Laboratories, L.P., Fort Worth, TX, USA

PRM4
A4
A SCOPING LITERATURE REVIEW ON THE EXTERNAL VALIDITY OF RANDOMIZED CONTROLLED TRIAL POPULATIONS
Curtis SE1, Kennedy-Martin T2, Faries DE1, Robinson S2, Johnston JA1
1Eli Lilly and Company, Indianapolis, IN, USA, 2Kennedy Martin Health Outcomes, East Sussex, UK

PRM5
WITHDRAWN

PRM6
A5
ESTIMATION OF LONG-TERM CARE NEEDS FOR 9 MAJOR CANCER IN TAIWAN
Hung M1, Lai W2, Hwang J3, Wang J4
1Department of Public Health, National Cheng Kung University Medical College, Tainan, Taiwan, 2Department of Surgery, National Cheng Kung University Hospital, College of Medicine, National Cheng Kung University, Tainan, Taiwan, 3Academia Sinica, Taipei, Taiwan, 4National Cheng Kung University College of Medicine, Tainan, Taiwan

PRM7
A6
ROLE OF TELEREHABILITATION IN PATIENTS FOLLOWING TOTAL KNEE ARTHROPLASTY: EVIDENCE FROM SYSTEMATIC LITERATURE REVIEW
Shukla H, Nair SR, Shaikh JS, Thakker D, Sharma D
Capita India Pvt. Ltd., Mumbai, India

PRM8
A7
DIFFICULTY IN ESTABLISHING THE IMPACT OF DRUGS ON QUALITY OF LIFE IN COGNITIVELY IMPAIRED PATIENTS: EXAMPLE OF ATTEMPTING TO DERIVE UTILITY IN PATIENTS TREATED WITH RIFAXIMIN-α FOR THE REDUCTION OF RECURRENCE OF EPISODES OF HEPATIC ENCEPHALOPATHY
Berni E1, Conway P2, Nanuwa K3, Currie CJ4
1Pharmatelligence, Cardiff, UK, 2Norgine Ltd, Harefield, UK, 3Norgine Ltd, Uxbridge, UK, 4Cardiff University, Cardiff, UK

PRM9
A8
THE IMPLEMENTATION OF THE EXTRACT OF CENTARIA ISLANDICA IN PATIENTS SUFFERING FROM EGZACERBATION OF CHRONIC PHARYNGITIS
Raskovic A, Savovic S, Stilinovic N, Milijasevic B
Faculty of Medicine, University of Novi Sad, Novi Sad, Serbia and Montenegro

PRM10
A9
INCORPORATING ADAPTIVE CLINICAL TRIALS IN NETWORK META-ANALYSIS
Thorlund K
Redwood Outcomes, Vancouver, BC, Canada

PRM11
A10
VALIDATION OF THE TELEPHONE-ADMINISTERED OF THE AGE AND STAGE QUESTIONNAIRE AND THE REVISED-PRESCREENING DENVER QUESTIONNAIRE: RESULTS FROM THE OTIS ANTIDEPRESSANTS IN PREGNANCY STUDY
Karam F1, Sheehy O2, Huneau M2, Chambers C3, Fraser W4, Johnson D5, Kao K3, Martin B2, Riordan SH6, Roth M7, st-André M8, Lavigne Voyer S9, Wolfe L10, Bérard A1
1University of Montreal, Montreal, QC, Canada, 2CHU Ste Justine, Montreal, QC, Canada, 3UCSD, San Diego, CA, USA, 4Faculty of Medicine, University of Montreal, Montreal, QC, Canada, 5California Teratogen Information Service, San Diego, CA, USA, 6, 7New York Teratogen Information Service, 8Université de Montréal, Montreal, QC, Canada, 9University of Connecticut Health Center, West Hartford, CT, USA, 10University of North Texas, TX, Denton, TX, USA

PRM12
WITHDRAWN

PRM13
A11
VALIDATION OF CLAIMS DATA TO IDENTIFY SURGICAL SITE INFECTIONS WITH ANTIBIOTIC UTILIZATION DATA
Warren DK1, Nickel KB1, Wallace AE2, Mines D2, Fraser VJ1, Olsen MA1
1Washington University School of Medicine, St. Louis, MO, USA, 2HealthCore, Inc, Wilmington, DE, USA

PRM14
A12
DEVELOPING A COHORT OF LINKED MOTHER-BABY PAIRS TO STUDY PRETERM LABOR: HARMONIZING REAL-WORLD DATA FROM FOUR LARGE U.S. INTEGRATED DELIVERY NETWORKS
Greenacre A1, Mack C2, Dreyer NA1, Pimenta J3
1Quintiles, Cambridge, MA, USA, 2Quintiles, Durham, NC, USA, 3GSK, Uxbridge, Middlesex, UK

PRM15
A13
SOME STATISTICAL CONSIDERATIONS IN ESTIMATING A DISEASE PROGRESSION MODEL FOR CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD)
Exuzides A1, Colby C2, Briggs A3, Riseborough N4, Baker TM5, Ismaila A6
1ICON plc, San Francisco, CA, USA, 2ICON, San Francisco, CA, USA, 3University of Glasgow, Glasgow, UK, 4ICON, Toronto, ON, Canada, 5ICON plc (formerly Oxford Outcomes), Morristown, NJ, USA, 6GlaxoSmithKline, Research Triangle Park, NC, USA

PRM16
A14
CAUSAL INFERENCE: COGNITIVE FUNCTIONING AND DEPRESSIVE SYMPTOMS BY LONGITUDINAL MARGINAL STRUCTURE MODEL
Yao P
Northern Illinois University, Dekalb, IL, USA

PRM17
A15
METHODS FOR EVALUATING THE EFFECT MODIFICATION IN THE OBSERVATIONAL STUDIES: A RETROSPECTIVE ANALYSIS ON THE IMPACT OF SIMVASTATINA AND EZETIMIBE AND STATINS ON ACUTE MYOCARDIAL INFARCTION
Voci C
Agenzia Sanitaria e Sociale Emilia-Romagna, Bologna, Italy

PRM18
A16
MULTI-CRITERIA DECISION ANALYSIS IN ONCOLOGY: AN OVERVIEW
Adunlin G1, Diaby V1, Montero A2, Xiao H1
1Florida A&M University, Tallahassee, FL, USA, 2Cleveland Clinic, Clevland, OH, USA

PRM19
B1
A COMPARISON OF PROPENSITY SCORES FOR ASSESSING PATIENT REPORTED OUTCOMES: A MONTE CARLO STUDY
Spielmann R1, Kuhn E1, Ochs L1, Koh WY2, Tu C1
1University of New England, Portland, ME, USA, 2University of New England, Biddeford, ME, USA

PRM20
B2
BARRIERS IN CONDUCTING RESEARCH IN THE FIELD OF RADIOLOGY: PERCEPTIONS OF HEALTH CARE PROFESSIONALS FROM A DEVELOPING NATION
Beg M
The Aga Khan University Hospital, Karachi, Pakistan

PRM21
B3
VIEWS OF HEALTHCARE PROVIDERS ON MEDICAL ERRORS IN KARACHI, PAKISTAN
Beg M
The Aga Khan University Hospital, Karachi, Pakistan

RESEARCH ON METHODS - Cost Methods
PRM22
B4
EVALUATING THE RELATIONSHIP BETWEEN BODY MASS INDEX (BMI) OF DIABETIC PATIENTS AND HEALTHCARE COSTS
Adeyemi A1, Rascati KL2, Lawson KA1, Barner JC1, Wilson J1, Novak S1
1The University of Texas at Austin, Austin, TX, USA, 2The University of Texas at Austin, College of Pharmacy, Austin, TX, USA

PRM23
B5
THE LONG-TERM ECONOMIC VALUE OF A NEW-BORN CHILD COMPARISON OF THE HUMAN CAPITAL AND THE LIFETIME INVESTMENT APPROACHES
Gáspár K1, Kaló Z2, Ágh T1, Vámossy I3, Lehmann M4, Nagy B1
1Syreon Research Institute, Budapest, Hungary, 2Eotvos Lorand University (ELTE), Budapest, Hungary, 3Gedeon Richter Plc, Budapest, Hungary, 4PregLem SA, Geneva, Switzerland

PRM24
B6
HOW TO DEAL WITH MISSING LONGITUDINAL DATA IN COST OF ILLNESS MODELS IN ALZHEIMER'S DISEASE – SUGGESTIONS FROM THE GERAS STUDY RESULTS
Belger M1, Haro JM2, Reed C1, Happich M3, Kahle-Wrobleski K4, Wimo A5
1Eli Lilly & Company Limited, Windlesham, UK, 2Parc Sanitari Sant Joan de Déu, CIBERSAM, Universitat de Barcelona, Barcelona, Spain, 3Eli Lilly and Company, Bad Homburg, Germany, 4Eli Lilly and Company, Indianapolis, IN, USA, 5Karolinska Institutet, Stockholm, Sweden

PRM25
B7
IN SEARCH OF LOST COSTS: THE IMPLICATIONS FOR COST-EFFECTIVENESS RESEARCH WHEN THE PRICE ISN'T RIGHT
Lupinetti P, Suko J, Johnson T, Matuszewski K
First Databank, South San Francisco, CA, USA

PRM26
B8
A REVIEW OF NICE TECHNOLOGY APPRAISALS USING SINGLE-ARM TRIALS
Purser M1, Mladsi DM1, Wolowacz S2
1RTI Health Solutions, Research Triangle Park, NC, USA, 2RTI Health Solutions, Manchester, UK

PRM27
B9
QUANTIFYING THE EFFICIENCY OF HEALTH CARE INTERVENTIONS: A REVIEW OF TIME AND MOTION STUDIES PRESENTED AT ISPOR CONFERENCES BETWEEN 2008 AND 2013
Kritikou P1, De Cock E2
1UBC: An Express Scripts Company, London, UK, 2UBC: An Express Scripts Company, Barcelona, Spain

PRM28
B10
WHAT ARE INDIRECT COSTS IN NEURODEGENERATIVE DISEASES? A METHODOLOGICAL REVIEW
Costa N, Deruemaux-Burel H, Molinier L
University Hospital of Toulouse, Toulouse, France

PRM29
B11
NOT AS EASY AS IT SOUNDS: CHALLENGES IN ASSESSING THE VALUE FOR MONEY OF IMPLEMENTED VACCINATION PROGRAMS
Newall AT1, Reyes J1, Wood JG1, McIntyre PB2, Menzies R2, Beutels P3
1University of New South Wales, Sydney, Australia, 2National Centre for Immunisation Research and Surveillance (NCIRS), Sydney, Australia, 3University of Antwerp, Antwerp, Belgium

PRM30
B12
ESTIMATING THE COST OF HEALTHCARE ASSOCIATED INFECTIONS CONTROLLING FOR BOTH PATIENT VARIABILITY AND TIME-DEPENDENT BIAS
Shi W1, Greco G1, Gelijns A1, Blackstone E2, Moskowitz A1, O'Gara P3, Jeffries N4, Bagiella E1
1Icahn School of Medicine at Mount Sinai, New York, NY, USA, 2Cleveland Clinic Foundation, Cleveland, OH, USA, 3Brigham and Women's Hospital, Boston, MA, USA, 4National Heart, Lung and Blood Institute, Bethesda, MD, USA

PRM31
B13
PERFORMANCE COMPARISON OF DIFFERENT TYPES OF PROPENSITY SCORE MATCHING ALGORITHMS IN A STUDY OF RARE DISEASE TREATMENT COST COMPARISON USING REAL WORLD EVIDENCE
Han Y, Lodowski N
WG Consulting, New York, NY, USA

PRM32
WITHDRAWN

PRM33
B14
NON-ALCOHOLIC STEATOHEPATITIS CLINICAL DEVELOPMENT: AN OPPORTUNITY FOR NON-INVASIVE SERUM OR IMAGING BIOMARKERS FROM A COST-EFFICIENCY PERSPECTIVE
Agnese W, Suciu S, Liu S, Sood V, Cooreman M
Mitsubishi Tanabe Pharma America, Inc., Jersey city, NJ, USA

RESEARCH ON METHODS - Databases & Management Methods
PRM34
B15
ALCOHOL AND SUBSTANCE USE DISORDER COMORBIDITY MEASURES: WHO IS BEING COUNTED?
Montejano LB
Truven Health Analytics, Cambridge, MA, USA

PRM35
B16
EMPIRICAL INVESTIGATION OF TECHNIQUES FOR HANDLING MISSING COST-TO-CHARGE RATIO (CCR) IN NATIONWIDE INPATIENT SAMPLE (NIS)
Yu T1, Zhou H2
1Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA, 2KMK Consulting Inc., Florham Park, NJ, USA

PRM36
C1
DEVELOPMENT OF A SPATIALLY-ENABLED PUBLIC-USE DATABASE FOR END-STAGE RENAL DISEASE POLICY STUDIES
Stephens M1, Maione-Downing B1, Brotherton SA1, Gitlin MD2
1Prima Health Analytics, Weymouth, MA, USA, 2InnoPeritus, Geneva, Switzerland

PRM37
C2
PERFORMANCE OF NLP TOOL DESIGNED TO IDENTIFY AND EXTRACT BIOLOGIC DRUG INFUSION DATA FROM CLINICAL NOTES
Leng J1, Lu C1, Cannon G2, Teng C1, Zhou X1, He T1, Harrison DJ3, Shah N3, Sauer BC1
1Departments of Internal Medicine, University of Utah, Salt Lake City, UT, USA, 2VA Salt Lake City Health Care System, Salt Lake City, UT, USA, 3Amgen, Inc, Thousand Oaks, CA, USA

PRM38
C3
BUILDING A BRIDGE: ICD-9-CM TO ICD-10-CM MAPPING CHALLENGES AND SOLUTIONS
Seare J1, Yang J2, Yu S2, Zarotsky V1
1Optum, Eden Prairie, MN, USA, 2Takeda Pharmaceuticals International, Inc., Deerfield, IL, USA

PRM39
C4
USE OF A COMMON DATA MODEL TO FACILITATE RAPID ANALYTICS SUPPORTING HEALTH OUTCOMES RESEARCH
Kim H1, Joo S"1, Anstatt D1, Morrison J1, Germscheid L2, Murray R2
1Bristol-Myers Squibb Company, Pennington, NJ, USA, 2UBC, Harrisburg, PA, USA

PRM40
C5
ACCURACY OF A NATURAL LANGUAGE PROCESSING SOFTWARE DESIGNED TO COMPUTE AVERAGE WEEKLY DOSE FROM NARRATIVE MEDICATION SCHEDULE
Lu C1, Leng J1, Cannon G2, Zhou X1, Harrison DJ3, Shah N3, Sauer BC1
1Departments of Internal Medicine, University of Utah, Salt Lake City, UT, USA, 2VA Salt Lake City Health Care System, Salt Lake City, UT, USA, 3Amgen, Inc, Thousand Oaks, CA, USA

PRM41
C6
ALL PAYER CLAIMS DATABASES, STATE BASED SOLUTIONS TO LEVELING THE HEALTH DATA INFORMATION PLAYING FIELD
Garfield S1, Noyes S2, Armstrong S3
1GfK Market Access, Wayland, MA, USA, 2Human Services Research Institute, Cambridge, MA, USA, 3GfK, Wayland, MA, USA

PRM42
C7
BUILDING A REAL-WORLD NON-SMALL CELL LUNG CANCER COHORT BY LINKING A CLAIMS DATABASE TO ONCOLOGY ELECTRONIC MEDICAL RECORDS
Chen C1, Wade RL2, Khan N1, Pokras SM3, Semonelli C1, Zeng S1, Marcus M1
1IMS Health, Plymouth Meeting, PA, USA, 2IMS Health, Parsippany, NJ, USA, 3IMS Health, Alexandria, VA, USA

PRM43
C8
REAL WORLD RESEARCH IN LATIN AMERICA: OPPORTUNITIES, SOURCES AND BARRIERS
Gregory V1, Barbeau M1, Machnicki G2, Voko Z3, Heisel O4, Keown P4
1Novartis Pharmaceuticals Canada Inc., Dorval, QC, Canada, 2Novartis Argentina SA, Buenos Aires, Argentina, 3Syreon Research Institute, Budapest, Hungary, 4Syreon Corporation, Vancouver, BC, Canada

PRM44
C9
EVALUATION OF CURRENT DATA SOURCES IN EUROPE FOR THE CONDUCT OF REAL-WORLD STUDIES ON LUNG AND RENAL CELL CARCINOMA: A SYSTEMATIC LITERATURE REVIEW
Gridchyna I1, Manley Daumont M2, Yousif A1, Hirji I2, Lees M2, Salvo F3, Moride Y1
1Faculty of Pharmacy, Université de Montréal, Montreal, QC, Canada, 2Global Health Economics and Outcomes Research - Europe, Bristol-Myers Squibb, Rueil-Malmaison, France, 3Bordeaux University, CHU Bordeaux, Bordeaux, France

PRM45
C10
UTILITZATION OF THE TRUVEN NATIONAL WEIGHTS TO ESTIMATE THE CHRONIC CONDITIONS AND THEIR ASSOCIATED QUALITY MEASURES IN THE U.S. COMMERCIAL EMPLOYER SPONSORED HEALTH INSURED POPULATION
Carroll C, Priest J, Lu CX, Le HV
GlaxoSmithKline, RTP, NC, USA

PRM46
C11
OVERVIEW OF PATIENT-CENTERED OUTCOME MEASURES AVAILABLE IN THE PATIENT-REPORTED OUTCOME AND QUALITY OF LIFE INSTRUMENTS DATABASE (PROQOLID) FOR USE IN QUEBEC
Perrier L1, Conway K2, Acquadro C1
1Mapi Research Trust, Lyon, France, 2MAPI Research Trust, Lyon, France

PRM47
C12
MANAGING CONGENITAL AND PEDIATRIC CARDIAC SURGERY DATA BASE: THE IMPACT ON CLINCIAL PRACTICE AND QUALITY OF CARE
Furnaz S
Aga Khan University and Hospital, Karachi, Pakistan

PRM48
C13
IDENTIFYING REAL-WORLD DATA FOR OBSERVATIONAL STUDIES: A SYSTEMATIC APPROACH
Smoyer-Tomic KE1, Young KC1, Winchester C2
1Oxford PharmaGenesis™ Inc, Newtown, PA, USA, 2Oxford PharmaGenesis™ Ltd, Oxford, UK

PRM49
C14
A SOFTWARE PLATFORM TO SYNTHESIZE EVIDENCE FROM HETEROGENEOUS DATA SOURCES
Shum K, Zheng P, Dinh T, Azimi M, Inumpudi A
Evidera, San Francisco, CA, USA

PRM50
C15
THE APPLICATION OF BIG DATA ANALYTICS AND HIGH PERFORMANCE COMPUTING TO DELIVER INSTANT INSIGHT ON LONGITUDINAL DISEASE MANAGEMENT
Khosla S
AstraZeneca, Macclesfield, UK

PRM51
C16
APPLICATION OF SURVIVAL ANALYSIS TO ADULT PNEUMOCOCCAL VACCINATION RATE IN THE UNITED STATES
Zhang D, Yang HK, Huang M
Merck & Co., Inc, West Point, PA, USA

PRM52
D1
FROM PRIVATE SITES TO BIG DATA WITHOUT COMPROMISING PRIVACY: A CASE OF NEUROIMAGING DATA CLASSIFICATION
Plis S1, Sarwate A2, Turner J3, Arbabshirani M1, Calhoun V1
1The Mind Research Network, Albuquerque, NM, USA, 2Rutgers, The State University of New Jersey, Piscataway, NM, USA, 3Georgia State University, Atlanta, GA, USA

RESEARCH ON METHODS - Modeling Methods
PRM53
D2
THE IMPACT OF ALTERNATIVE ESTIMATES OF DISUTILITIES ASSOCIATED WITH HYPOGLYCEMIA ON NET QALYS: CANAGLIFLOZIN VERSUS SITAGLIPTIN AS ADD-ON THERAPY IN INDIVIDUALS WITH TYPE 2 DIABETES MELLITUS (T2DM) INADEQUATELY CONTROLLED ON A BACKGROUND OF METFORMIN (MET) PLUS SULFONYLUREA (SU) IN THE CANADIAN SETTING
Yoong K1, Willis M2, Johansen P3, Yim C1, Teschemaker A4, Neslusan C4
1Janssen, Inc., Toronto, ON, Canada, 2The Swedish Institute for Health Economics, Lund, Sweden, 3The Swedish Institute for Health Economics (IHE), Lund, Sweden, 4Janssen Global Services, LLC, Raritan, NJ, USA

PRM54
D3
RISK HETEROGENEITY IN CLINICAL TRIALS: AN EVALUATION OF 25 LARGE CLINICAL TRIALS USING INDIVIDUAL PATIENT DATA
Kent DM1, Nelson J2, Altman DG3, Hayward RA4
1Tufts Medical Center/Tufts University School of Medicine, Boston, MA, USA, 2Tufts Medical Center, Boston, MA, USA, 3University of Oxford, Oxford, MA, USA, 4University of Michigan, Ann Arbor, MI, USA

PRM55
D4
DEALING WITH COMPETING RISKS IN DIABETES MELLITUS: COMPARISON OF RESULTS USING A MARKOV VERSUS A MICRO-MARKOV SIMULATION MODEL
Wetering, van de G, Verheggen B
Pharmerit International, Rotterdam, The Netherlands

PRM56
D5
OPTIMAL INFORMATION ACQUISITION POLICIES: APPLICATION TO HEPATITIS C SCREENING
Cipriano LE1, Liu S2, Weber TA3, Goldhaber-Fiebert JD4
1Ivey Business School, Western University, London, ON, Canada, 2University of Washington, Seattle, WA, USA, 3Ecole Polytechnique Fédérale de Lausanne, Lausanne, Switzerland, 4Stanford University, Stanford, CA, USA

PRM57
D6
FRONTIERS IN PEDIATRIC HEALTH TECHNOLOGY ASSESSMENT: DEVELOPMENT OF A DISCRETE EVENT SIMULATION MODEL FOR ECONOMIC EVALUATION OF SCREENING, DIAGNOSIS AND TREATMENT STRATEGIES IN AUTISM SPECTRUM DISORDER
Zur RM, Carter MT, Scherer SW, Ungar WJ
Hospital for Sick Children, Toronto, ON, Canada

PRM58
D7
PREDICTING HEART FAILURE RECURRENCE AFTER AORTIC VALVE REPLACEMENT USING A COMPETING-RISKS MODEL
Chan V1, Anderson LH2, Martinson M3, Koullick M4, Ruel M5
1University of Ottawa Heart Institute, Ottawa, ON, 2Technomics Research, Ottawa, ON, Canada, 3Technomics Research, LLC, Ottawa, ON, Canada, 4St. Jude Medical, Ottawa, ON, Canada, 5University of Ottawa Heart Institute, Ottawa, ON, Canada

PRM59
D8
HEMATOPOIETIC STEM CELL TRANSPLANTATION OUTCOMES: LOGISTIC REGRESSION MODEL DEVELOPMENT
Hatfield MD1, Kramer MA2, Johnson ML1
1University of Houston, Houston, TX, USA, 2The University of Texas MD Anderson Cancer Center, Houston, TX, USA

PRM60
D9
THE ESTIMATE OF VACCINATION COVERAGE RATE USING TRANSMISSON DYNAMIC MODEL: A EXAMPLE OF PNEUMOCOCCUS VACCINES
Chang CJ1, Wen Y2, Fann CS3
1Chang Gung University, Kwei-Shan, Taoyuan, Taiwan, 2Chang Gung University, Taoyuan, Taiwan, 3Academia Sinica, Taipei, Taiwan

PRM61
D10
PHYSICIANS'ATTRIBUTES AND REVERSED CONJOINT ANALYSIS
Huttin C
ENDEPUSresearch,Inc, Cambridge, MA, USA

PRM62
D11
INCORPORATING A PHARMACOMETRIC MODEL-BASED META-ANALYSIS INTO A HEALTH ECONOMIC MICROSIMULATION MODEL OF COPD
Slejko JF1, Ribbing J2, Willke RJ3
1University of Washington, Seattle, WA, USA, 2Pfizer, Silverdal, Sweden, 3Pfizer, Inc., New York, NY, USA

PRM63
D12
A GUIDE ON HOW TO SPEEDUP COMPUTATION TIME IN CE-MODELS USING VBA OR MULTI-PROCESS PROGRAMMING IN C++
Khorshid M, Thuresson P, Ray J
F. Hoffmann-La Roche Ltd., Basel, Switzerland

PRM64
D13
A MODEL SIMULATING EXTERNAL REFERENCE PRICING TO SUPPORT POLICY DECISION MAKING IN EUROPE
Vataire A1, Cetinsoy L2, Rémuzat C1, Aballea S1, Toumi M3
1Creativ-Ceutical, Paris, France, 2Creativ-Ceutical, PARIS, France, 3University Claude Bernard Lyon 1, Lyon, France

PRM65
D14
REVIEW OF MODELS USED IN ECONOMIC ANALYSES OF NEW ORAL TREATMENTS FOR TYPE 2 DIABETES MELLITUS
Asche C1, Eurich DT2, Hippler S1
1University of Illinois, Peoria, IL, USA, 2University of Alberta, Edmonton, AB, Canada

PRM66
D15
ESTIMATING THE TIME TRADE-OFF VALUES OF THE EQ-5D-5L HEALTH STATES IN URBAN CHINA
Luo N1, Liu G2, Li M3
1National University of Singapore, Singapore, Singapore, 2Peking University, Beijing, China, 3University of Maryland School of Pharmacy, Baltimore, MD, USA

PRM67
D16
IDENTIFYING AND CHARACTERIZING TRAJECTORIES OF QOL IN PERSONS WITH ADVANCED CANCER: IMPORTANT CONTRIBUTORS TO DECREASING QOL IN PEOPLE WITH CANCER
Rodriguez AM, Gagnon B, Mayo NE
McGill University, Montreal, QC, Canada

PRM68
E1
BIAS WHEN ADJUSTING FOR SURROGATES OF CONFOUNDERS
Page JH, Chia VM
Amgen, Inc, Thousand Oaks, CA, USA

PRM69
E2
SIZE DISTORTION OF HYPOTHESIS TESTS FOR TWO-STAGE LEAST SQUARES MODEL: WHAT THE RULE OF THUMB CAN'T GIVE YOU?
Shao H, Shi L
Tulane University, New Orleans, LA, USA

PRM70
E3
DEPRESSION AND COMORBID OBESITY AND HYPERTENSION IN US CHILDREN
Tevie J1, Shaya FT2
1University of Maryland, Baltimore, MD, USA, 2University of Maryland School of Pharmacy, Baltimore, MD, USA

PRM71
E4
ANXIETY AND COMORBID OBESITY AND HYPERTENSION IN US CHILDREN
Tevie J1, Shaya FT2
1University of Maryland, Baltimore, MD, USA, 2University of Maryland School of Pharmacy, Baltimore, MD, USA

PRM72
E5
THE IMPACT OF TWO DIFFERENT CASE DEFINITIONS OF MAJOR CONGENITAL MALFORMATIONS IDENTIFIED FROM QUEBEC (CANADA) ADMINISTRATIVE DATABASES ON THEIR ASSOCIATION WITH ASTHMA CONTROLLER MEDICATIONS TAKEN DURING PREGNANCY
Eltonsy S, Blais L
University of Montreal, Montreal, QC, Canada

PRM73
E6
SURVIVAL MODELING FOR THE ESTIMATION OF TRANSITION PROBABILITIES IN MODEL-BASED ECONOMIC EVALUATIONS IN THE ABSENCE OF INDIVIDUAL PATIENT DATA: A TUTORIAL
Diaby V1, Adunlin G1, Montero A2
1Florida A&M University, Tallahassee, FL, USA, 2Cleveland Clinic, Clevland, OH, USA

PRM74
E7
THE INHERENT BIAS FROM USING PARTITIONED SURVIVAL MODELS IN ECONOMIC EVALUATION
Coyle D1, Coyle K2
1University of Ottawa, Ottawa, ON, Canada, 2Brunel University, Uxbridge, ON, Canada

RESEARCH ON METHODS - Patient-Reported Outcomes Studies
PRM75
E8
PSYCHOMETRIC VALIDATION OF PATIENT-REPORTED OUTCOME MEASURES OF PAIN IN U.S. PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS
Naegeli AN1, Al Sawah S1, Tomaszewski EL2, Gemmen E3
1Eli Lilly and Company, Indianapolis, IN, USA, 2Quintiles, Pittsburgh, PA, USA, 3Quintiles, Rockville, MD, USA

PRM76
E9
PSYCHOMETRIC PROPERTIES OF THE WORLD HEALTH ORGANIZATION'S QUALITY OF LIFE-BREF INSTRUMENT (WHOQOL-BREF) AMONG ADULTS WITH AUTISM
Jariwala K1, Khanna R2, West-Strum D2, Bentley JP2, Banahan BF2, Holmes ER2, Barnard M2
1University of Mississippi, Oxford, MS, USA, 2University of Mississippi, University, MS, USA

PRM77
E10
DO EQ-5D AND SF-6D ASK THE RIGHT QUESTIONS IN MENTAL HEALTH? A CONTENT VALIDATION USING INTERVIEWS WITH PATIENTS
Brazier JE, Connell J, O'Cathain A
University of Sheffield, Sheffield, UK

PRM78
E11
A COMPARISON OF THE UTILITY OF VARIANTS OF THE CHARLSON COMORBIDITY INDEX (CCI) IN PREDICTING PATIENT-REPORTED HEALTH OUTCOMES
Witt EA1, Goren A2
1Kantar Health, Princeton, NJ, USA, 2Kantar Health, New York, NY, USA

PRM79
E12
SYSTEMATIC REVIEW OF THE Q-TWIST IN ONCOLOGY
Solem CT, Wan Y, Botteman MF
Pharmerit International, Bethesda, MD, USA

PRM80
E13
EQ-5D HEALTH UTILITIES ARE ESTIMATED SUBJECT TO CONSIDERABLE UNCERTAINTY
Pullenayegum EM1, Xie F2
1Hospital for Sick Children, Toronto, ON, Canada, 2McMaster University, Hamilton, ON, Canada

PRM81
E14
LAM EMPLOYMENT ABSENCE AND PRODUCTIVITY SCALE (LEAPS): FURTHER VALIDATION STUDIES IN MAJOR DEPRESSIVE DISORDER
Lam RW
University of British Columbia, Vancouver, BC, Canada

PRM82
E15
USING VISUAL AIDES IN TRANSLATION OF A SPASTICITY SYMPTOM QUESTIONNAIRE
Brandt BA1, Talbert M2, McKown S3, Gawlicki MC1, Bernardi K3
1Corporate Translations, Inc., East Hartford, CT, USA, 2Corporate Translations Inc., Chicago, IL, USA, 3Corporate Translations, Inc., Chicago, IL, USA

PRM83
E16
PSYCHOMETRIC PROPERTIES OF THE BRIEF FATIGUE INVENTORY-SHORT FORM IN SYSTEMIC LUPUS ERYTHEMATOSUS
Al Sawah S1, Tomaszewski EL2, Gemmen E3, Naegeli A1
1Eli Lilly and Company, Inc., Indianapolis, IN, USA, 2Quintiles, Pittsburgh, PA, USA, 3Quintiles, Rockville, MD, USA

PRM84
F1
DEVELOPMENT AND VALIDATION OF THE FATIGUE SYMPTOMS AND IMPACTS QUESTIONNAIRE – RELAPSING MULTIPLE SCLEROSIS (FSIQ-RMS™)
Stokes J1, Schüler R2, Yaworsky A1, Hunsche E2
1Adelphi Values, Boston, MA, USA, 2Actelion Pharmaceuticals Ltd, Allschwil, Switzerland

PRM85
F2
SYSTEMATIC REVIEW OF MEASURES OF PERSONAL RECOVERY USED IN SCHIZOPHRENIA
Shillington A1, Benson C2, Frye C3
1EPI-Q Inc., Oak Brook, IL, USA, 2Janssen Scientific Affairs, LLC, Titusville, NJ, USA, 3EPI-Q, Inc., Oak Brook, IL, USA

PRM86
WITHDRAWN

PRM87
F3
ONLINE SOCIAL NETWORKS-BASED QUALITATIVE RESEARCH TO IDENTIFY PATIENT-RELEVANT CONCEPTS IN CHRONIC LYMPHOCYTIC LEUKEMIA
McCarrier KP1, Bull S2, Simacek KF3, Wicks P3, Pierson RF4, Wolfe M1, Cella D5, Rothman M6
1Health Research Associates, Inc., Seattle, WA, USA, 2Janssen Global Services, LLC, Fremont, CA, USA, 3PatientsLikeMe, Cambridge, MA, USA, 4Janssen Global Services, LLC, Raritan, NJ, USA, 5Northwestern University, Chicago, IL, USA, 6Janssen Global Services, LLC, Spring House, PA, USA

PRM88
F4
EVALUATION OF DIMENSIONALITY IN PHYSICAL FUNCTIONING CONSTRUCT WHEN COMBINING THE HEALTH ASSESSMENT QUESTIONNAIRE WITH THE SF-36® HEALTH SURVEY PHYSICAL FUNCTIONING SCALE
Lin C1, Al Sawah S1, Zhu B1, Wyrwich K2, Kawata A2, Zhang X1, Naegeli AN1
1Eli Lilly and Company, Indianapolis, IN, USA, 2Evidera, Bethesda, MD, USA

PRM89
F5
HOW WELL DO GENERIC PROMIS FATIGUE MEASURES PERFORM IN RHEUMATOID ARTHRITIS?
Bartlett SJ1, Orbai AM2, Jones M2, Bingham CO2
1McGill University, Montreal, QC, Canada, 2Johns Hopkins University, Baltimore, MD, USA

PRM90
F6
COMPARISON OF THE 4-ITEM AND 8-ITEM MORISKY MEDICATION ADHERENCE SCALE IN PATIENTS WITH TYPE 2 DIABETES
Pedersini R1, Vietri J2
1Kantar Health, Epsom, UK, 2Kantar Health, Milan, Italy

PRM91
F7
LINGUISTIC VALIDATION OF THE DTSQ: CHALLENGES WITH ARABIC AND FRENCH FOR ALGERIA
Dawsey R1, Sweeney E1, Plowright R2, Wilson A2, Bradley C3
1TransPerfect, Atlanta, GA, USA, 2Health Psychology Research, Ltd, Eghan, Surrey, UK, 3Health Psychology Research Unit, Royal Holloway University of London, and Health Psychology Research Ltd., Surrey, UK

PRM92
F8
DESIGN OF A DISCRETE CHOICE EXPERIMENT FOR PREFERENCES ELICITATION OF ELDERLY POPULATION TOWARDS DEPRESSION
Monteiro AL1, Santos MS1, Cintra MA1, Pereira CC2, Floriano DB1, Plotkowski LM3
1National Institute of Cardiology, Rio de Janeiro, Brazil, 2Oswaldo Cruz Foundation, Rio de Janeiro, RJ, Brazil, 3Centro de Estudos e Pesquisa do Envelhecimento, Rio de Janeiro, Brazil

PRM93
F9
COMPARING STANDARD GAMBLE AND VISUAL ANALOG SCALE MEASURES OF UTILITY FOR ERECTILE DYSFUNCTION HEALTH STATE
Bakken DG1, Tomaszewski K1, Wasserman D1, Claeys C2
1KJT Group, Inc., Honeoye Falls, NY, USA, 2KJT Group Inc., Honeoye Falls, NY, USA

PRM94
F10
INTEGRATING THE CHILD'S VOICE IN ADVERSE EVENT REPORTING IN ONCOLOGY TRIALS: INITIAL STEPS IN THE PEDIATRIC PRO-CTCAE INITIATIVE
Reeve BB1, Withycombe J2, Tomlinson D3, Sung L3, Mowbray C4, Martens C1, Mack JW5, Lyons JC1, Kohler RK1, Keller S4, Jacobs SS4, Gold SH1, Freyer DR6, Baker JN7, Hinds PS4
1University of North Carolina at Chapel Hill, Chapel Hill, NC, USA, 2Palmetto Health Children's Hospital, Columbia, SC, USA, 3The Hospital for Sick Children, Toronto, ON, Canada, 4Children's National Medical Center, Washington, DC, USA, 5Harvard Medical School, Boston, MA, USA, 6University of Southern California, Los Angeles, CA, USA, 7St Jude Children's Research Hospital, Memphis, TN, USA

PRM95
F11
AN OPEN RESEARCH EXCHANGE FOR ONLINE PATIENT FEEDBACK IN PRO DEVELOPMENT
Harrington M, Heywood B, Rura S, Wicks P
PatientsLikeMe, Cambridge, MA, USA

PRM96
F12
META-ANALYSIS OF PREFERENCE-BASED QUALITY OF LIFE VALUES IN HEART FAILURE
Stevanovic J1, Pehlivanoglou P2, Postma MJ1
1University of Groningen, Groningen, The Netherlands, 2Toronto Health Economics and Technology Assessment, Toronto, ON, Canada

PRM97
F13
DEVELOPMENT AND PSYCHOMETRIC EVALUATION OF A CANINE DERMATITIS QUALITY OF LIFE QUESTIONNAIRE: RESULTS FROM THREE CLINICAL TRIALS
Postorino-Reeves N1, Brohan E2, Tatlock S3, Panter C3, Amodie D1, Gasper S1
1Zoetis, Florham Park, NJ, USA, 2Adelphi Values Ltd, Manchester, UK, 3Adelphi Values Ltd, Bollington, UK

PRM98
F14
DATA QUALITY WITH MIXED-MODE ADMINISTRATION OF THE SHORT FORM-36
Broering JM1, Paciorek A1, Carroll P2, Wilson LS1, Litwin MS3, Miaskowski C1
1University of California San Francisco, San Francisco, CA, USA, 2University of California, San Francisco, San Francisco, CA, USA, 3University of California Los Angeles, Los Angeles, CA, USA

PRM99
F15
ALGORITHMS TO ESTIMATE HEALTH UTILITIES FROM TOTAL JOINT ARTHROPLASTY DISEASE-SPECIFIC MEASURES
Odum SM, Troyer JL
UNC-Charlotte, Charlotte, NC, USA

PRM100
F16
EQUIVALENCE OF ELECTRONIC AND PAPER ADMINISTRATION OF PATIENT REPORTED OUTCOME MEASURES: A SYSTEMATIC REVIEW AND META-ANALYSIS
Wild D1, Muehlhausen W1, O Donohoe P2, Doll H1
1ICON, Oxford, UK, 2CRF Health, London, UK

PRM101
G1
DEVELOPMENT OF THE BEHAVIOR RATING INVENTORY OF EXECUTIVE FUNCTION (BRIEF) IN FIVE LANGUAGES
Vasarri S1, Acquadro C2, Isquith PK3
1Mapi, Lyon, France, 2Mapi Research Trust, Lyon, France, 3Dartmouth University, Norwich, VT, USA

PRM102
WITHDRAWN

PRM103
G2
ASSESSING THE CONTENT VALIDITY OF THE ENDOMETRIOSIS SYMPTOM DIARY AND ENDOMETRIOSIS IMPACT SCALE
Gater A1, Wichmann K2, Seitz C2, Gerlinger C2, Taylor F3, Chen W4, Filonenko A2
1Adelphi Values, Bollington, UK, 2Bayer Pharma AG, Berlin, Germany, 3Adelphi Values USA, Boston, MA, USA, 4RTI Health Solutions, Research Triangle Park, NC, USA

PRM104
G3
MEASUREMENT PROPERTIES OF PAINDETECT BY SEVERITY OF NEUROPATHIC PAIN
Sadosky A1, Cappelleri JC2, Parliyan A3, Koduru V4
1Pfizer, New York, NY, USA, 2Pfizer Global Pharmaceuticals, New York, NY, USA, 3Pfizer, Inc., New York, NY, USA, 4Eliassen Group, New London, CT, USA

PRM105
G4
ELICITATION OF HEALTH-RELATED QUALITY OF LIFE CONCEPTS ASSOCIATED WITH PERIPHERAL NEUROPATHY
Hawken NA1, Holmstrom S2, Aballea S3, Odeyemi IA4, Toumi M5, van Nooten FE6
1Creativ-Ceutical, Luxembourg, Luxembourg, 2HEOR, Astellas Pharma Global Development, Leiden, The Netherlands, 3Creativ-Ceutical, Paris, France, 4Astellas Pharma Europe Ltd, Chertsey, UK, 5University Claude Bernard Lyon 1, Lyon, France, 6Astellas, Leiden, The Netherlands

PRM106
G5
VALIDATION OF FACT-LYM AND FACIT-FATIGUE AS SCALES MEASURING OF HEALTH-RELATED QUALITY OF LIFE OF PATIENTS WITH MYELOPROLIFERATIVE SYNDROMES IN COLOMBIA
Romero M1, Marrugo R1, Simbaqueba E2
1Fundacion Salutia, Bogota, Colombia, 2Institución Universitaria Colegios de Colombia - UNICOC, Bogota, Colombia

PRM107
G6
THE ALLAIS PARADOX IN THE SELF-PERCEPTION OF QUALITY OF LIFE
Moreno M
Instituto de Evaluación Tecnológica en Salud - IETS, Bogotá D.C., Colombia

PRM108
G7
THE IMPORTANCE OF DEVELOPING COUNTRY-SPECIFIC VERSIONS OF SPANISH-LANGUAGE CLINICAL OUTCOME ASSESSMENTS (COAS) DURING LINGUISTIC VALIDATION
Sweeney E1, Popielnicki A2
1TransPerfect, New York, NY, USA, 2TransPerfect, Boston, MA, USA

PRM109
G8
THE CHALLENGE OF TRANSLATING THE STORY MEMORY SUBTEST OF THE REPEATABLE BATTERY FOR THE ASSESSMENT OF NEUROPSYCHOLOGICAL STATUS (RBANS) INTO 24 LANGUAGES
Grataloup G1, Chandler J2
1Mapi, Lyon, France, 2Merck, North Wales, PA, USA

PRM110
G9
STANDARDIZATION OF MENTAL HEALTH ASSESSMENT – USING ITEM RESPONSE THEORY (IRT) TO CROSS-CALIBRATE TWO SELF-REPORTED MENTAL HEALTH TOOLS: THE PATIENT HEALTH QUESTIONNAIRE (PHQ-9) AND THE SF-36V2 MENTAL HEALTH (MH) SCALE
Bjorner JB, White MK, Yarlas AS
Optum, Lincoln, RI, USA

PRM111
G10
INTERNAL VALIDATION OF MAPPING ANALYSES FOR HEALTH TECHNOLOGY ASSESSMENT
Trueman D, Treharne C
Abacus International, Bicester, UK

PRM112
G11
A SYSTEMATIC REVIEW OF METHODOLOGICAL FRAMEWORKS FOR EVALUATION OF ETHICAL CONSIDERATIONS IN HEALTH TECHNOLOGY ASSESSMENT
Assasi N, Schwartz L, Tarride J, Campbell K, Goeree R
McMaster University, Hamilton, ON, Canada

RESEARCH ON METHODS - Statistical Methods
PRM113
G12
COMPARING PROPENSITY SCORE, PROPENSITY SCORE WITH COVARIATES AND GENETIC ALGORITHM METHODS FOR COVARIATE MATCHING IN OBSERVATIONAL STUDIES
Claeys C1, Bakken DG2, Wasserman D2, Spilman J2
1KJT Group Inc., Honeoye Falls, NY, USA, 2KJT Group, Inc., Honeoye Falls, NY, USA

PRM114
G13
ARE INDUSTRY FUNDED NETWORK META-ANALYSES LOWER QUALITY?
Chambers JD1, Gunjal SS2, Winn A3, Kennedy IR4, Hoey MG5, Pyo J1
1Tufts Medical Center, Boston, MA, USA, 2University of Houston, Houston, TX, USA, 3The University of North Carolina at Chapel Hill, Chapel Hill, NC, USA, 4Daisy Hill Hospital, Newry, UK, 5Downe Hospital, Downpatrick, UK

PRM115
G14
AUTOMATIC DEVELOPMENT OF CLINICAL PREDICTION MODELS WITH GENETIC PROGRAMMING: A CASE STUDY IN CARDIOVASCULAR DISEASE
Bannister CA, Currie CJ, Preece A, Spasic I
Cardiff University, Cardiff, UK

PRM116
G15
IMPROVED BOOTSTRAP POINT AND CONFIDENCE INTERVAL ESTIMATION OF THE INCREMENTAL COST-EFFECTIVENESS RATIO (ICER)
Skrepnek GH1, Sahai A2
1The University of Oklahoma Health Sciences Center, Oklahoma City, OK, USA, 2The University of The West Indies, St. Augustine, Trinidad and Tobago

PRM117
G16
USING MULTIPLE IMPUTATION FOR MISSING VALUES TO IDENTIFY CHRONIC KIDNEY DISSEASE STAGES
Cai Y1, Jiao X2
1IMS Health, Plymouth Meeting, PA, USA, 2IMS Health, Plymouthmeeting, PA, USA

PRM118
G17
IDENTIFY CHF AND COPD PAITIENTS AT HIGH RISK OF HOSPITALIZATION: USING PREDICTIVE ANALYTICS FOR PATIENT OUTREACH
Wang QC, Higgins SL, Chawla R, Nigam S
Independence Blue Cross, Philadelphia, PA, USA

PRM119
G18
AN ANALYTICAL METHOD FOR ESTIMATING THE BOUNDARIES OF AN INCREMENTAL COST-EFFECTIVENESS RATIO
Kamae I1, Yamabe K2, Sugimoto T1
1The University of Tokyo, Graduate School of Public Policy, Tokyo, Japan, 2HTA and Public Policy Project, Graduate School of Public Policy, The University of Tokyo, Tokyo, Japan

PRM120
G19
BIAS WHEN USING PROPENSITY SCORE METHODS TO ADJUST FOR COVARIATES THAT ARE NOT CONFOUNDERS
Chia VM, Page JH
Amgen, Inc, Thousand Oaks, CA, USA

PRM121
G20
EFFICIENT ESTIMATION OF THE INCREMENTAL COST-EFFECTIVENESS RATIO (ICER) USING A NEW PERSPECTIVE
Skrepnek GH1, Sahai A2
1The University of Oklahoma Health Sciences Center, Oklahoma City, OK, USA, 2The University of The West Indies, St. Augustine, Trinidad and Tobago

PRM122
G21
SURVIVAL CROSSOVER ADJUSTMENT AND COST EFFECTIVENESS ANALYSIS: AN EMPIRICAL AND METHODOLOGICAL REVIEW WITH APPLICATION
Hopkins RB1, Campbell K1, Burke N1, Levine M1, Thabane L1, Duong M2, Shum D2, Goeree R1
1McMaster University, Hamilton, ON, Canada, 2Hoffmann-La Roche Limited, Mississauga, ON, Canada

PRM123
H1
A MICROSOFT-EXCEL BASED TOOL FOR RUNNING AND CRITICALLY APPRAISING SIMPLE NETWORK META-ANALYSES USING WINBUGS – AN OVERVIEW AND APPLICATION
Brown ST1, Cameron C2, Grima DT1, Wells G3
1Cornerstone Research Group, Burlington, ON, Canada, 2University of Ottawa, Ottawa, ON, Canada, 3University of Ottawa Heart Institute, Ottawa, ON, Canada

PRM124
H2
MATCHING WITH MULTIPLE CONTROL GROUPS TO MAXIMIZE USE OF REGISTRY DATA FROM PATIENTS WITH SCHIZOPHRENIA
Lopatto J1, Song X2, Juneau P3, Benson C1, Olson WH4, Fastenau J1
1Janssen Scientific Affairs, LLC, Titusville, NJ, USA, 2Truven Health Analytics, Cambridge, MA, USA, 3Truven Health Analytics, Boyds, MD, USA, 4Janssen Pharmaceuticals, Inc., Titusville, NJ, USA

RESEARCH ON METHODS - Study Design
PRM125
H3
RISK ON USING LOGISTIC REGRESSION TO ILLUSTRATE EXPOSURE-RESPONSE RELATIONSHIP OF INFECTIOUS DISEASE
Ren J, Asche C, Kirkness CS
University of Illinois, Peoria, IL, USA

PRM126
H4
BURDEN OF NARCOLEPSY DISEASE (BOND) STUDY: VALIDATION OF USING A SINGLE DIAGNOSIS CODE TO DEFINE PRESENCE OF AN ORPHAN CONDITION IN MEDICAL CLAIMS DATA
Villa K1, Reaven N2, Funk S2, McGaughey K3, Ohayon M4, Guilleminault C4, Ruoff C4, Black J4
1Jazz Pharmaceuticals, Palo Alto, CA, USA, 2Strategic Health Resources, La Canada, CA, USA, 3Cal Poly State University, San Luis Obispo, CA, USA, 4Stanford University Center for Sleep Research and Medicine, Redwood City, CA, USA

PRM127
H5
DOES THE USE OF A SURROGATE OUTCOME IN SOLID STATE ONCOLOGY HTAS DECREASE THE CHANCES OF POSITIVE RECOMMENDATIONS?
Jaksa A, Ho YS, Rubinstein E, Daniel K
Context Matters, Inc., New York, NY, USA

PRM128
H6
CRITICAL APPRAISAL OF NON-RANDOMIZED CONTROLLED TRIALS – A REVIEW OF RECOMMENDED AND COMMONLY USED TOOLS
Quigley JM1, Thompson J1, Halfpenny N1, Scott DA2
1ICON Health Economics, Oxford, UK, 2ICON Clinical Research UK Ltd., Oxford, UK

PRM129
H7
HYBRID TIME AND MOTION, PATIENT SURVEY AND CHART REVIEW STUDY METHODOLOGY: A CASE STUDY OF SUBCUTANEOUS ALLERGEN IMMUNOTHERAPY IN THE US AND CANADA
Yeomans K1, Payne KA1, Blume SW2, Tao S1, Hubbard SM3, Allen-Ramey F4
1UBC: An Express Scripts Company, Dorval, QC, Canada, 2Evidera, Bethesda, MD, USA, 3UBC: An Express Scripts Company, Lexington, MA, USA, 4Merck & Co. Inc., West Point, PA, USA

PRM130
H8
REGISTRY: ITS USE IN REAL-WORLD DATA COLLECTION
Pan YI1, Dieck G2, Stemhagen A3
1UBC: An Express Scripts Company, Dorval, QC, Canada, 2UBC: An Express Scripts Company, Blue Bell, QC, Canada, 3UBC: An Express Scripts Company, Blue Bell, PA, USA

PRM131
H9
NOVEL APPROACHES TO PATIENT RECRUITMENT AND DATA INTEGRATION
Hanson KA1, Dudka P2, Payne KA1, Beatty M3, Frazee SG4
1United BioSource Corporation, Dorval, QC, Canada, 2UBC: An Express Scripts Company, McLean, VA, USA, 3UBC: An Express Scripts Company, Orlando, FL, USA, 4Express Scripts, Inc., St. Louis, MO, USA

RESEARCH ON METHODS - Conceptual Papers
PRM132
H10
WHAT ARE THE ROLES OF HEALTH ECONOMIC MODELS IN PRODUCT DEVELOPMENT?
Wu E, Davies GM, Koglin J, Cook J
Merck, North Wales, PA, USA

PRM133
H11
USING SURROGATE ENDPOINTS FOR HEATH ECONOMIC ANALYSIS: WHAT IS THE ROLE OF STATISTICAL VALIDATION?
Briggs A1, Hawkins N2, Spencer M3
1University of Glasgow, Glasgow, UK, 2ICON., Oxford, UK, 3Janssen, High Wycombe, UK

PRM134
H12
STANDARDIZING CRITERIA FOR COGNITIVE ASSESSMENT OF PAPER-TO-ELECTRONIC EQUIVALENCE OF PROS
Martin ML, McCarrier KP
Health Research Associates, Inc., Seattle, WA, USA

PRM135
H13
RISKS, IMPACTS, AND MITIGATION OF MISSING EPRO DATA ON CLINICAL TRIALS
Holzbaur E, Ross J
Almac Clinical Technologies, Souderton, PA, USA

PRM136
H14
METHODOLOGICAL AND OPERATIONAL CONSIDERATIONS IN CONDUCTING RETROSPECTIVE MEDICAL CHART REVIEW STUDIES IN HOSPITALS AND MEDICAL CENTERS IN EMERGING MARKETS
Solem CT1, Macahilig CP2, Katyal M2, Li JZ3, Haider S4, Raghubir N5, Stephens JM1
1Pharmerit International, Bethesda, MD, USA, 2Medical Data Analytics, Parsippany, NJ, USA, 3Pfizer, Inc., San Diego, CA, USA, 4Pfizer Inc, Groton, CT, USA, 5Pfizer, New York, NY, USA

PRM137
WITHDRAWN

PRM138
H15
A FRAMEWORK FOR ANALYSING TREATMENT SEQUENCES: INCORPORATING TIME DEPENDENT TRANSITIONS THROUGH PARTITIONED SURVIVAL ANALYSIS
Briggs A1, Sidhu M2, Baker T3
1University of Glasgow, Glasgow, UK, 2ICON Plc, Morristown, NJ, USA, 3ICON, Morristown, NJ, USA

PRM139
H16
A COMPREHENSIVE ECONOMIC AND PRICING MODELING FRAMEWORK FOR UNDERSTANDING ORPHAN DRUG DEVELOPMENT
Mallow PJ1, Rizzo JA2, Irish W3, Okere CE4
1S2 Statistical Solutions, Cincinnati, OH, USA, 2Stony Brook University, Port Jefferson, NY, USA, 3CTI Clinical Trial and Consulting Services, Raleigh, NC, USA, 4CTI Clinical Trial and Consulting Services, Cincinnati, OH, USA

PRM140
H17
CONCEPTUAL MODEL DEVELOPMENT AND PROS FOR NON-DIABETIC PERIPHERAL NEUROPATHIC PAIN
Chambers C1, Ernault E2, van Nooten FE3
1Astellas Pharma Europe Ltd, Chertsey, UK, 2Astellas Pharma Europe B.V., Leiden, UK, 3Astellas, Leiden, The Netherlands

PRM141
H18
MODELING ALL-CAUSE MORTALITY IN HEALTH ECONOMIC MODELS
Hernandez L, Altincatal A, Pelligra C
Evidera, Lexington, MA, USA

PRM142
H19
JOINT BAYESIAN NETWORK META-ANALYSIS FOR EVENT COUNTS AND HAZARDS – COMPARISON OF METHODS AND IMPLEMENTATIONS
Schmidt H, Nehmiz G
Boehringer Ingelheim Pharma GmbH & Co KG, Biberach, Germany

PRM143
H20
PRACTICAL ISSUES WHEN CONDUCTING NETWORK META-ANALYSES WITH A LIMITED NUMBER OF STUDIES
Odom D, Chirila C, Sherrill B, Wang J
RTI Health Solutions, Research Triangle Park, NC, USA

PRM144
H21
EXPLORING THE IMPACT OF STRUCTURAL UNCERTAINTY IN PARTITIONED SURVIVAL MODELS FOR ONCOLOGY
Beca J1, Hoch JS2
1St. Michael's Hospital, Toronto, ON, Canada, 2University of Toronto, Toronto, ON, Canada

PRM145
I1
THE CHALLENGES OF PILOT TESTING TRANSLATED PRO MEASURES WITH CHILDREN
Two R1, Currie D1, Browning R1, Loten M1, Herdman M2
1PharmaQuest Ltd, Banbury, UK, 2Insight Consulting & Research, Mataró, Spain

PRM146
I2
QUANTIFYING THE IMPACT OF PROGRESSION ON SURVIVAL IN ONCOLOGY: AN APPLICATION OF STATISTICAL MODELING FRAMEWORK TO MEASURE THE IMPACT OF EVENTS ON SUBSEQUENT RISKS
Ishak KJ, Proskorovsky I
Evidera, St-Laurent, QC, Canada

PRM147
I3
AUTOMATIC CREATION OF DISEASE MODELS USING DATA MINING TECHNIQUES ON DATA FROM A CLINICAL CANCER REGISTRY
Pobiruchin M1, Bochum S2, Martens UM2, Kieser M3, Schramm W1
1Heilbronn University, Heilbronn, Germany, 2SLK-Kliniken Heilbronn GmbH, Heilbronn, Germany, 3University of Heidelberg, Heidelberg, Germany

PRM148
I4
CONTINUOUS PATIENT ENGAGEMENT IN COMPARATIVE EFFECTIVENESS RESEARCH (CER): AN APPLICATION IN CARDIOVASCULAR DISEASE (CVD)
Vandigo J, Oloyede E, Abdulhalim AM, Mullins CD
University of Maryland School of Pharmacy, Baltimore, MD, USA

PRM149
WITHDRAWN

PRM150
I5
VALUE OF RARE DISEASE NON-INTERVENTIONAL STUDIES TO SUPPORT PAYER & CLINICAL DESCISION MAKING
Degun R, Patel D, Marinsek N, Chalmers M
Navigant, London, UK

PRM151
I6
PUBLICATION OF METHODOLOGICAL GUIDELINES: THE DEVELOPMENT OF SYSTEMATIC REVIEWS (SR) AND META-ANALYSES OF RANDOMIZED CLINICAL TRIALS BY THE DEPARTMENT OF SCIENCE AND TECHNOLOGY OF THE BRAZILIAN MINISTRY OF HEALTH (DECIT/MOH)
Elias FT1, Koury Cd2
1Ministry of Health of Brazil, Brasilia, Brazil, 2FIPE -Fundação de Ensino e Pesquisas Econômicas, Brasilia, Brazil

PRM152
I7
COLLECTING PROS IN PATIENT REGISTRIES: THE NEED FOR AND POTENTIAL IMPACT OF PROVIDING PRO DATA TO THE TREATING PHYSICIAN – AND WHEN
Gemmen E1, Leavy MB2
1Quintiles, Rockville, MD, USA, 2Quintiles Real World & Late Phase, Cambridge, MA, USA

PRM153
I8
PRACTICAL APPROACHES TO ACHIEVING REAL-WORLD STUDY DATA REPRESENTATIVE OF THE TARGET POPULATION
Gemmen E1, Parmenter L2, Mendelsohn AB3
1Quintiles, Rockville, MD, USA, 2Quintiles Real World & Late Phase, Reading, UK, 3Quintiles Real World & Late Phase, Rockville, MD, USA

PRM154
I9
UTILIZATION OF UNMANNED AIRCRAFT SYSTEMS (UAS) FOR EMERGENCY MEDICAL SITUATIONS IN RURAL COMMUNITIES: A VISION FOR THE FUTURE
Spitsberg R1, Jones C2
1Univeristy of Vermont - College of Medicine, Burlington, VT, USA, 2University of Vermont, Burlington, VT, USA

PRM155
WITHDRAWN

PRM156
I10
PUBLICATION MANUAL OF BUDGET IMPACT ANALYSIS (BIA) BY THE DEPARTMENT OF SCIENCE AND TECHNOLOGY OF THE MINISTRY OF HEALTH (DECIT)
Koury Cd1, Elias FT2
1FIPE -Fundação de Ensino e Pesquisas Econômicas, Brasilia, Brazil, 2Ministry of Health of Brazil, Brasilia, Brazil

PRM157
I11
MIXED METHODS FOR THE DEVELOPMENT OF CLINCIAL OUTCOME ASSESSMENTS (COAS): EXPLORING FURTHER POSSIBILITIES FOR MIXED DATA COLLECTION AND ANALYSIS
Willgoss TG1, Humphrey L1, Symonds T2, Cappelleri JC3
1Abacus International, Manchester, UK, 2Pfizer Ltd, Tadworth, Surrey, UK, 3Pfizer Global Pharmaceuticals, New York, NY, USA

PRM158
I12
SIMULTANEOUS ITEM DEVELOPMENT (SID) FOR CLINICAL OUTCOMES ASSESSMENTS (COAS)
Humphrey L, Willgoss TG
Abacus International, Manchester, UK

PRM159
WITHDRAWN

PRM160
I13
SCIENTIFIC PRODUCTION ANALYSIS ON HEALTH ECONOMICS IN LATIN AMERICA BASED ON THE CLASSIFICATION METHODOLOGY OF WAGSTAFF AND CULYER
Simbaqueba E1, Ochoa F2, Brito K3
1Institución Universitaria Colegios de Colombia - UNICOC, Bogota, Colombia, 2Salutia Foundation, Bogota, Colombia, 3

PRM161
I14
RESOURCE MODELLING: THE MISSING PIECE OF THE HTA JIGSAW?
Thokala P, Dixon S
University of Sheffield, Sheffield, UK

Contact ISPOR @ info@ispor.org | View Legal Disclaimer
© 2018 International Society for Pharmacoeconomics and Outcomes Research.
All rights reserved under International and Pan-American Copyright Conventions.